[NO and atherosclerosis].
Ohtani
Kisho
K
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University.
Egashira
Kensuke
K
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001120:Arginine / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015316:Genetic Therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension / Q000150:complications; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000096:biosynthesis / Q000502:physiology* / Q000627:therapeutic use; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D019001:Nitric Oxide Synthase / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D052250:Nitric Oxide Synthase Type III; D011341:Probucol / Q000494:pharmacology / Q000627:therapeutic use; D012307:Risk Factors; D013314:Stress, Mechanical
D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020030:Nitric Oxide Donors; D009569:Nitric Oxide; D001120:Arginine; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D011341:Probucol; D019331:NG-Nitroarginine Methyl Ester